This pitch creative was based on the positioning of ELEPSIA XR, a Sun Pharmaceuticals drug, as the best choice for all patients receiving 1,000 mg or more per day of levetiracetam. ELEPSIA XR is the preferred formulation of levetiracetam that provides the best seizure control because new 1,500 mg and 1,000 mg dosage strengths, delivered through Wrap Matrix Technology, provide steady plasma levels in the most simple-to-take regimen so that Neurologists can be confident that their patients receive the protection they intended.
My core responsibilities were to lead the launch pitch as Art Supervisor, to direct art teams to keep concepts on strategy, and to build the final presentation art and logo explorations.